Hadiqa Shahid creator Supervisor : Dr. Aneeqa Noor text monographic 151p. Soft Copy 30cm Shahid, Hadiqa Diabetes mellitus, a chronic metabolic disorder affecting over 589 million adults globally, induces diabetes-associated cognitive impairment and peripheral neuropathy through sustained hyperglycemia, oxidative stress, neuroinflammation, and blood-brain barrier dysfunction. Existing therapies inadequately target both central and peripheral neural damage due to poor blood-brain barrier penetration. This study developed cinnamon barkderived carbon nanodots (CIN-CNDs) conjugated with chenodeoxycholic acid (CINCDCA) via green hydrothermal synthesis as a novel nanotherapeutic for diabetesassociated complications. Characterization using UV-Visible spectroscopy, Fourier Transform Infrared spectroscopy (FTIR), Atomic Force Microscopy (AFM), and Scanning Electron Microscopy (SEM) confirmed nanoscale particle formation (average 4.4 nm), successful functionalization, and surface morphology suitable for biomedical applications. Physicochemical testing demonstrated excellent hemocompatibility (<5% hemolysis), high drug loading efficiency (85 ± 3%), pH-stable hydrolytic stability across physiological ranges, and controlled sustained release profile over 72 hours. In streptozotocin-induced diabetic mice, CIN-CDCA nanoconjugates (10 mg/kg, i.p., 1, 4, 14 days) showed significant improvements across comprehensive neuropathic pain assessments (cold allodynia, hot plate, paw pressure, tail immersion; all p<0.01) and cognitive function tests (Morris water maze, Y-maze, novel object recognition, open field).CIN-CDCA nanoconjugates demonstrate biocompatibility, targeted delivery, and disease-modifying efficacy for diabetes-associated neural complications, warranting clinical translation. MS Biomedical Sciences (BMS) 610 http://10.250.8.41:8080/xmlui/handle/123456789/57138 http://10.250.8.41:8080/xmlui/handle/123456789/57138